196 related articles for article (PubMed ID: 36095215)
1. Nanobodies and chemical cross-links advance the structural and functional analysis of PI3Kα.
Hart JR; Liu X; Pan C; Liang A; Ueno L; Xu Y; Quezada A; Zou X; Yang S; Zhou Q; Schoonooghe S; Hassanzadeh-Ghassabeh G; Xia T; Shui W; Yang D; Vogt PK; Wang MW
Proc Natl Acad Sci U S A; 2022 Sep; 119(38):e2210769119. PubMed ID: 36095215
[TBL] [Abstract][Full Text] [Related]
2. Structural and mechanistic insights provided by single particle cryo-EM analysis of phosphoinositide 3-kinase (PI3Kα).
Vogt PK; Hart JR; Yang S; Zhou Q; Yang D; Wang MW
Biochim Biophys Acta Rev Cancer; 2023 Sep; 1878(5):188947. PubMed ID: 37394020
[TBL] [Abstract][Full Text] [Related]
3. Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation.
Liu X; Yang S; Hart JR; Xu Y; Zou X; Zhang H; Zhou Q; Xia T; Zhang Y; Yang D; Wang MW; Vogt PK
Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725156
[TBL] [Abstract][Full Text] [Related]
4. Calmodulin (CaM) Activates PI3Kα by Targeting the "Soft" CaM-Binding Motifs in Both the nSH2 and cSH2 Domains of p85α.
Zhang M; Li Z; Wang G; Jang H; Sacks DB; Zhang J; Gaponenko V; Nussinov R
J Phys Chem B; 2018 Dec; 122(49):11137-11146. PubMed ID: 30047727
[TBL] [Abstract][Full Text] [Related]
5. Defining How Oncogenic and Developmental Mutations of PIK3R1 Alter the Regulation of Class IA Phosphoinositide 3-Kinases.
Dornan GL; Stariha JTB; Rathinaswamy MK; Powell CJ; Boulanger MJ; Burke JE
Structure; 2020 Feb; 28(2):145-156.e5. PubMed ID: 31831213
[TBL] [Abstract][Full Text] [Related]
6. Interaction of Calmodulin with the cSH2 Domain of the p85 Regulatory Subunit.
Wang G; Zhang M; Jang H; Lu S; Lin S; Chen G; Nussinov R; Zhang J; Gaponenko V
Biochemistry; 2018 Mar; 57(12):1917-1928. PubMed ID: 29494137
[TBL] [Abstract][Full Text] [Related]
7. Kinetic and structural analyses reveal residues in phosphoinositide 3-kinase α that are critical for catalysis and substrate recognition.
Maheshwari S; Miller MS; O'Meally R; Cole RN; Amzel LM; Gabelli SB
J Biol Chem; 2017 Aug; 292(33):13541-13550. PubMed ID: 28676499
[TBL] [Abstract][Full Text] [Related]
8. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
[TBL] [Abstract][Full Text] [Related]
9. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases.
Hon WC; Berndt A; Williams RL
Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714
[TBL] [Abstract][Full Text] [Related]
10. Computational Insights into the Interactions between Calmodulin and the c/nSH2 Domains of p85α Regulatory Subunit of PI3Kα: Implication for PI3Kα Activation by Calmodulin.
Ni D; Liu D; Zhang J; Lu S
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29300353
[TBL] [Abstract][Full Text] [Related]
11. Double
Vasan N; Razavi P; Johnson JL; Shao H; Shah H; Antoine A; Ladewig E; Gorelick A; Lin TY; Toska E; Xu G; Kazmi A; Chang MT; Taylor BS; Dickler MN; Jhaveri K; Chandarlapaty S; Rabadan R; Reznik E; Smith ML; Sebra R; Schimmoller F; Wilson TR; Friedman LS; Cantley LC; Scaltriti M; Baselga J
Science; 2019 Nov; 366(6466):714-723. PubMed ID: 31699932
[TBL] [Abstract][Full Text] [Related]
12. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
Hofmann BT; Jücker M
Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
[TBL] [Abstract][Full Text] [Related]
13. The structural basis for Ras activation of PI3Kα lipid kinase.
Zhang M; Jang H; Nussinov R
Phys Chem Chem Phys; 2019 Jun; 21(22):12021-12028. PubMed ID: 31135801
[TBL] [Abstract][Full Text] [Related]
14. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
[TBL] [Abstract][Full Text] [Related]
15. Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity.
Layton MJ; Saad M; Church NL; Pearson RB; Mitchell CA; Phillips WA
BMC Biochem; 2012 Dec; 13():30. PubMed ID: 23270540
[TBL] [Abstract][Full Text] [Related]
16. Assembly and Molecular Architecture of the Phosphoinositide 3-Kinase p85α Homodimer.
LoPiccolo J; Kim SJ; Shi Y; Wu B; Wu H; Chait BT; Singer RH; Sali A; Brenowitz M; Bresnick AR; Backer JM
J Biol Chem; 2015 Dec; 290(51):30390-405. PubMed ID: 26475863
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of the phosphoinositide 3-kinase p110δ interaction with p85α and membranes reveals aspects of regulation distinct from p110α.
Burke JE; Vadas O; Berndt A; Finegan T; Perisic O; Williams RL
Structure; 2011 Aug; 19(8):1127-37. PubMed ID: 21827948
[TBL] [Abstract][Full Text] [Related]
18. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
[TBL] [Abstract][Full Text] [Related]
19. Activation loop sequences confer substrate specificity to phosphoinositide 3-kinase alpha (PI3Kalpha ). Functions of lipid kinase-deficient PI3Kalpha in signaling.
Pirola L; Zvelebil MJ; Bulgarelli-Leva G; Van Obberghen E; Waterfield MD; Wymann MP
J Biol Chem; 2001 Jun; 276(24):21544-54. PubMed ID: 11278889
[TBL] [Abstract][Full Text] [Related]
20. Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations.
Leontiadou H; Galdadas I; Athanasiou C; Cournia Z
Sci Rep; 2018 Oct; 8(1):15544. PubMed ID: 30341384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
